Exclusive Summary

• - Off-patent for decades (US launch since the 1960s) with no IP barriers, enabling rapid entry in most markets.
• - Addresses mucus-related needs in COPD, asthma, bronchiectasis, and cystic fibrosis with a low-cost nebulized option across 10%/20% and 4–20 mL presentations.
• - US FDA ANDA (214177) and EU/US GMP manufacturing support broad market access and tender eligibility.
• - While generics exist, many markets face supply/format gaps; the full SKU set (unit-dose and larger vials) offers clear differentiation.
• - Typically delivers ≥70% acquisition cost savings vs originators and enzyme therapies (e.g., dornase alfa), creating strong pharmacoeconomic value.